attempted to manage steroid-refractory CRS by ruxolitinib for its ability to down regulate inflammatory cytokines including IL-1, IL-6, TNF-α and IFN-γ and demonstrated its effectiveness and safety in CRS (35). This evidence concerns the gene IFNG and congenital rubella syndrome.